Efficacy and interaction of antioxidant supplements as adjuvant therapy in cancer treatment: A systematic review

Integrative Cancer Therapies

Volumn 15, Issue 1, 2016, Pages 17-39

  Yasueda, Asuka ^a   Urushima, Hayato ^a   Ito, Toshinori ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antioxidant; Cancer; Chemotherapy; Radiotherapy; Supplement; Vitamin

Indexed keywords

ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ARGININE; ASCORBIC ACID; CAROTENOID; COUMARIN; CURCUMIN; ELLAGIC ACID; MELATONIN; POLYPHENOL DERIVATIVE; RETINOL; SELENIUM; THIOCTIC ACID; TOCOPHEROL; UBIDECARENONE; ZINC; POLYPHENOL; UBIQUINONE; FREE RADICAL; REACTIVE OXYGEN METABOLITE; VITAMIN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DIET SUPPLEMENTATION; DIZZINESS; DRUG SAFETY; EPIGASTRIC PAIN; HEADACHE; HEARTBURN; HUMAN; HYPERTRANSAMINASEMIA; INSOMNIA; IRRITABILITY; MALABSORPTION; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; OXIDATIVE STRESS; PHOTOPHOBIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT; DNA DAMAGE; DRUG EFFICACY; ENERGY YIELD; ENZYME ACTIVITY; HEART FUNCTION; LIPID PEROXIDATION; NONHUMAN; OUTCOME ASSESSMENT; REVIEW; SUPPLEMENTATION; TREATMENT RESPONSE; DIETARY SUPPLEMENT; DRUG EFFECTS; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PROCEDURES;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; COMBINED MODALITY THERAPY; DIETARY SUPPLEMENTS; FREE RADICALS; HUMANS; NEOPLASMS; OXIDATIVE STRESS; POLYPHENOLS; REACTIVE OXYGEN SPECIES; TREATMENT OUTCOME; VITAMINS;

EID: 84960438711     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735415610427     Document Type: Article

References (130)

1. Ito T, Urushima H, Sakaue M, et al. Reduction of adverse effects by a mushroom product, active hexose correlated compound (AHCC) in patients with advanced cancer during chemotherapy: the significance of the levels of HHV-6 DNA in saliva as a surrogate biomarker during chemotherapy. Nutr Cancer. 2014;66:377-382.
2. Hyodo I, Amano N, Eguchi K, et al. Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol. 2005;23:2645-2654.
3. Ziech D, Franco R, Georgakilas AG, et al. The role of reactive oxygen species and oxidative stress in environmental carcinogenesis and biomarker development. Chem Biol Interact. 2010;188:334-339.
4. Fuchs-Tarlovsky V. Role of antioxidants in cancer therapy. Nutrition. 2013;29(1):15-21.
5. Lamson DW, Brignall MS. Antioxidants in cancer therapy: their actions and interactions with oncologic therapies. Altern Med Rev. 1999;4:304-329.
6. Labriola D, Livingston R. Possible interactions between dietary antioxidants and chemotherapy. Oncology (Williston Park). 1999;13:1003-1008, discussion 1008, 1011-1002.
7. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007;297:842-857.
8. Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C. Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials. Cancer Treat Rev. 2007;33:407-418.
9. National Cancer Institute. Antioxidants and Cancer Prevention: Fact Sheet. Bethesda, MD: National Cancer Institute. Accessed September 28, 2015. Website. http://www.cancer.gov/about-cancer/causes-prevention/risk/diet/antioxidants-fact-sheet
10. Abrams DI, Weil A. Integrative Oncology. Oxford, UK: Oxford University Press; 2009.
11. Weisburger JH. Nutritional approach to cancer prevention with emphasis on vitamins, antioxidants, and carotenoids. Am J Clin Nutr. 1991;53(1, suppl):S226-S237.
12. Houston MC. Treatment of hypertension with nutraceuticals, vitamins, antioxidants and minerals. Expert Rev Cardiovasc Ther. 2007;5:681-691.
13. Mangge H, Becker K, Fuchs D, Gostner JM. Antioxidants, inflammation and cardiovascular disease. World J Cardiol. 2014;6:462-477.
14. Crane FL, Sun IL, Sun EE. The essential functions of coenzyme Q. Clin Investig. 1993;71(8, suppl):S55-S59.
15. Nohl H, Gille L, Kozlov AV. Critical aspects of the antioxidant function of coenzyme Q in biomembranes. Biofactors. 1999;9:155-161.
16. Premkumar VG, Yuvaraj S, Sathish S, Shanthi P, Sachdanandam P. Anti-angiogenic potential of coenzyme Q10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy. Vascul Pharmacol. 2008;48:191-201.
17. Overvad K, Diamant B, Holm L, Holmer G, Mortensen SA, Stender S. Coenzyme Q10 in health and disease. Eur J Clin Nutr. 1999;53:764-770.
18. Baggio E, Gandini R, Plancher AC, Passeri M, Carmosino G. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure: CoQ10 Drug Surveillance Investigators. Mol Aspects Med. 1994;15(suppl):S287-S294.
19. Greenlee H, Shaw J, Lau YK, Naini A, Maurer M. Lack of effect of coenzyme q10 on doxorubicin cytotoxicity in breast cancer cell cultures. Integr Cancer Ther. 2012;11:243-250.
20. Conklin KA. Coenzyme q10 for prevention of anthracyclineinduced cardiotoxicity. Integr Cancer Ther. 2005;4:110-130.
21. Folkers K, Osterborg A, Nylander M, Morita M, Mellstedt H. Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem Biophys Res Commun. 1997;234:296-299.
22. Folkers K, Shizukuishi S, Takemura K, et al. Increase in levels of IgG in serum of patients treated with coenzyme Q10. Res Commun Chem Pathol Pharmacol. 1982;38:335-338.
23. Rusciani L, Proietti I, Paradisi A, et al. Recombinant interferon alpha-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-alpha and 5-year follow-up. Melanoma Res. 2007;17:177-183.
24. Akihama T, Nakamoto Y, Shindo T, Nakayama Y, Miura A. Protective effects of coenzyme Q10 on the adverse reactions of anthracycline antibiotics: using double blind method- with special reference to hair loss. Gan To Kagaku Ryoho. 1983;10:2125-2129.
25. Okuma K, Furuta I, Ota K. Protective effect of coenzyme Q10 in cardiotoxicity induced by adriamycin. Gan To Kagaku Ryoho. 1984;11:502-508.
26. Takimoto M, Sakurai T, Kodama K, et al. Protective effect of CoQ 10 administration on cardial toxicity in FAC therapy. Gan To Kagaku Ryoho. 1982;9:116-121.
27. Iarussi D, Auricchio U, Agretto A, et al. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol Aspects Med. 1994;15(suppl): S207-S212.
28. Lesser GJ, Case D, Stark N, et al. A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer. J Support Oncol. 2013;11(1): 31-42.
29. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science. 1977;197:165-167.
30. Tsubaki K, Horiuchi A, Kitani T, et al. Investigation of the preventive effect of CoQ10 against the side-effects of anthracycline antineoplastic agents. Gan To Kagaku Ryoho. 1984;11:1420-1427.
31. Bold RJ, Ishizuka J, Townsend CM Jr, Thompson JC. Alltrans- retinoic acid inhibits growth of human pancreatic cancer cell lines. Pancreas. 1996;12:189-195.
32. Frey JR, Peck R, Bollag W. Antiproliferative activity of retinoids, interferon alpha and their combination in five human transformed cell lines. Cancer Lett. 1991;57:223-227.
33. Tsurui K, Kosakai Y, Horie T, Awazu S. Vitamin A protects the small intestine from methotrexate-induced damage in rats. J Pharmacol Exp Ther. 1990;253:1278-1284.
34. Israel L, Hajji O, Grefft-Alami A, et al. Vitamin A augmentation of the effects of chemotherapy in metastatic breast cancers after menopause: randomized trial in 100 patients. Ann Med Interne (Paris). 1985;136:551-554.
35. Dagdemir A, Yildirim H, Aliyazicioglu Y, Kanber Y, Albayrak D, Acar S. Does vitamin A prevent high-dosemethotrexate- induced D-xylose malabsorption in children with cancer? Support Care Cancer. 2004;12:263-267.
36. Meyskens FL Jr, Kopecky KJ, Appelbaum FR, Balcerzak SP, Samlowski W, Hynes H. Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial. Leuk Res. 1995;19:605-612.
37. Khor SC, Abdul Karim N, Wan Ngah WZ, Mohd Yusof YA. Vitamin E in sarcopenia: current evidences on its role in prevention and treatment. Oxid Med Cell Longev. 2014;2014:914853.
38. Felemovicius I, Bonsack ME, Baptista ML, Delaney JP. Intestinal radioprotection by vitamin E (alpha-tocopherol). Ann Surg. 1995;222:504-508.
39. Kumar KS, Srinivasan V, Toles R, Jobe L, Seed TM. Nutritional approaches to radioprotection: vitamin E. Mil Med. 2002;167(2, suppl):S57-S59.
40. Bairati I, Meyer F, Gelinas M, et al. Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol. 2005;23:5805-5813.
41. Pathak AK, Bhutani M, Guleria R, et al. Chemotherapy alone vs. chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell lung cancer. J Am Coll Nutr. 2005;24:16-21.
42. Meyer F, Bairati I, Fortin A, et al. Interaction between antioxidant vitamin supplementation and cigarette smoking during radiation therapy in relation to long-term effects on recurrence and mortality: a randomized trial among head and neck cancer patients. Int J Cancer. 2008;122:1679-1683.
43. Fuchs-Tarlovsky V, Bejarano-Rosales M, Gutierrez-Salmean G, Casillas MA, Lopez-Alvarenga JC, Ceballos-Reyes GM. Effect of antioxidant supplementation over oxidative stress and quality of life in cervical cancer. Nutr Hosp. 2011;26: 819-826.
44. Suhail N, Bilal N, Khan HY, et al. Effect of vitamins C and E on antioxidant status of breast-cancer patients undergoing chemotherapy. J Clin Pharm Ther. 2012;37:22-26.
45. Ferreira PR, Fleck JF, Diehl A, et al. Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head Neck. 2004;26:313-321.
46. Pace A, Savarese A, Picardo M, et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol. 2003;21:927-931.
47. Kottschade LA, Sloan JA, Mazurczak MA, et al. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer. 2011;19:1769-1777.
48. Argyriou AA, Chroni E, Koutras A, et al. Preventing paclitaxel- induced peripheral neuropathy: a phase II trial of vitamin E supplementation. J Pain Symptom Manage. 2006;32: 237-244.
49. Argyriou AA, Chroni E, Koutras A, et al. A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support Care Cancer. 2006;14:1134-1140.
50. Pace A, Giannarelli D, Galie E, et al. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology. 2010;74:762-766.
51. Wadleigh RG, Redman RS, Graham ML, Krasnow SH, Anderson A, Cohen MH. Vitamin E in the treatment of chemotherapy-induced mucositis. Am J Med. 1992;92: 481-484.
52. Chitra S, Shyamala Devi CS. Effects of radiation and alphatocopherol on saliva flow rate, amylase activity, total protein and electrolyte levels in oral cavity cancer. Indian J Dent Res. 2008;19:213-218.
53. Ratnam DV, Ankola DD, Bhardwaj V, Sahana DK, Kumar MN. Role of antioxidants in prophylaxis and therapy: a pharmaceutical perspective. J Control Release. 2006;113:189-207.
54. Halperin EC, Gaspar L, George S, Darr D, Pinnell S. A double- blind, randomized, prospective trial to evaluate topical vitamin C solution for the prevention of radiation dermatitis: CNS Cancer Consortium. Int J Radiat Oncol Biol Phys. 1993;26:413-416.
55. Al-Delaimy WK, Ferrari P, Slimani N, et al. Plasma carotenoids as biomarkers of intake of fruits and vegetables: individual-level correlations in the European Prospective Investigation into Cancer and Nutrition (EPIC). Eur J Clin Nutr. 2005;59:1387-1396.
56. Schabath MB, Grossman HB, Delclos GL, et al. Dietary carotenoids and genetic instability modify bladder cancer risk. J Nutr. 2004;134:3362-3369.
57. Ansari MS, Gupta NP. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer. Urol Oncol. 2004;22:415-420.
58. Guttenplan JB, Chen M, Kosinska W, Thompson S, Zhao Z, Cohen LA. Effects of a lycopene-rich diet on spontaneous and benzo[a]pyrene-induced mutagenesis in prostate, colon and lungs of the lacZ mouse. Cancer Lett. 2001;164:1-6.
59. Fuchs-Tarlovsky V, Rivera MA, Altamirano KA, Lopez-Alvarenga JC, Ceballos-Reyes GM. Antioxidant supplementation has a positive effect on oxidative stress and hematological toxicity during oncology treatment in cervical cancer patients. Support Care Cancer. 2013;21:1359-1363.
60. Maestroni GJ, Covacci V, Conti A. Hematopoietic rescue via T-cell-dependent, endogenous granulocyte-macrophage colony-stimulating factor induced by the pineal neurohormone melatonin in tumor-bearing mice. Cancer Res. 1994;54: 2429-2432.
61. Ghielmini M, Pagani O, de Jong J, et al. Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer. Br J Cancer. 1999;80:1058-1061.
62. Brzezinski A. Melatonin in humans. N Engl J Med. 1997;336:186-195.
63. Lissoni P. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathol Biol (Paris). 2007;55: 201-204.
64. Lissoni P, Chilelli M, Villa S, Cerizza L, Tancini G. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res. 2003;35:12-15.
65. Lissoni P, Tancini G, Barni S, et al. Treatment of cancer chemotherapy- induced toxicity with the pineal hormone melatonin. Support Care Cancer. 1997;5:126-129.
66. Lissoni P, Barni S, Mandala M, et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer. 1999;35:1688-1692.
67. Cerea G, Vaghi M, Ardizzoia A, et al. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Anticancer Res. 2003;23:1951-1954.
68. Lissoni P. Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agent. Pathol Biol (Paris). 2007;55: 198-200.
69. Lissoni P, Paolorossi F, Ardizzoia A, et al. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J Pineal Res. 1997;23:15-19.
70. Karasek M, Winczyk K. Melatonin in humans. J Physiol Pharmacol. 2006;57(suppl 5):19-39.
71. Ibrahimpasic K. Alpha lipoic acid and glycaemic control in diabetic neuropathies at type 2 diabetes treatment. Med Arch. 2013;67:7-9.
72. Guo Y, Jones D, Palmer JL, et al. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer. 2014;22:1223-1231.
73. Kim J, Cho HJ, Sagong B, et al. Alpha-lipoic acid protects against cisplatin-induced ototoxicity via the regulation of MAPKs and proinflammatory cytokines. Biochem Biophys Res Commun. 2014;449:183-189.
74. Pantuck AJ, Leppert JT, Zomorodian N, et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res. 2006;12:4018-4026.
75. Perron NR, Brumaghim JL. A review of the antioxidant mechanisms of polyphenol compounds related to iron binding. Cell Biochem Biophys. 2009;53:75-100.
76. Ertam I, Mutlu B, Unal I, Alper S, Kivcak B, Ozer O. Efficiency of ellagic acid and arbutin in melasma: a randomized, prospective, open-label study. J Dermatol. 2008;35:570-574.
77. Amakura Y, Umino Y, Tsuji S, et al. Constituents and their antioxidative effects in eucalyptus leaf extract used as a natural food additive. Food Chem. 2002;77:47-56.
78. Smith WA, Gupta RC. Determining efficacy of cancer chemopreventive agents using a cell-free system concomitant with DNA adduction. Mutat Res. 1999;425:143-152.
79. Falsaperla M, Morgia G, Tartarone A, Ardito R, Romano G. Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate. Eur Urol. 2005;47:449-454, discussion 454-455.
80. Witaicenis A, Seito LN, da Silveira Chagas A, et al. Antioxidant and intestinal anti-inflammatory effects of plantderived coumarin derivatives. Phytomedicine. 2014;21: 240-246.
81. Rahimtula AD, Zachariah PK, O'Brien PJ. The effects of antioxidants on the metabolism and mutagenicity of benzo[a] pyrene in vitro. Biochem J. 1977;164:473-475.
82. Loprinzi CL, Kugler JW, Sloan JA, et al. Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. N Engl J Med. 1999;340:346-350.
83. Marshall ME, Butler K, Fried A. Phase I evaluation of coumarin (1, 2-benzopyrone) and cimetidine in patients with advanced malignancies. Mol Biother. 1991;3:170-178.
84. Grotz KA, Wustenberg P, Kohnen R, et al. Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer: a prospective, randomized, placebo-controlled, double-blind study. Br J Oral Maxillofac Surg. 2001;39:34-39.
85. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappa B-regulated gene products. Cancer Res. 2007;67:3853-3861.
86. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol. 2007;595:1-75.
87. Ryan JL, Heckler CE, Ling M, et al. Curcumin for radiation dermatitis: a randomized, double-blind, placebo-controlled clinical trial of thirty breast cancer patients. Radiat Res. 2013;180:34-43.
88. Kanai M, Yoshimura K, Asada M, et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol. 2011;68:157-164.
89. Epelbaum R, Schaffer M, Vizel B, Badmaev V, Bar-Sela G. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer. 2010;62:1137-1141.
90. Bayet-Robert M, Kwiatkowski F, Leheurteur M, et al. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther. 2010;9:8-14.
91. Kasperczyk S, Dobrakowski M, Kasperczyk A, Ostalowska A, Birkner E. The administration of N-acetylcysteine reduces oxidative stress and regulates glutathione metabolism in the blood cells of workers exposed to lead. Clin Toxicol (Phila). 2013;51:480-486.
92. Lin PC, Lee MY, Wang WS, et al. N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data. Support Care Cancer. 2006;14:484-487.
93. Ralph AP, Waramori G, Pontororing GJ, et al. l-Arginine and vitamin D adjunctive therapies in pulmonary tuberculosis: a randomised, double-blind, placebo-controlled trial. PLoS One. 2013;8:e70032.
94. Wang B, Liu Y, Feng L, et al. Effects of dietary arginine supplementation on growth performance, flesh quality, muscle antioxidant capacity and antioxidant-related signalling molecule expression in young grass carp (Ctenopharyngodon idella). Food Chem. 2015;167:91-99.
95. Heys SD, Ogston K, Miller I, et al. Potentiation of the response to chemotherapy in patients with breast cancer by dietary supplementation with L-arginine: results of a randomised controlled trial. Int J Oncol. 1998;12:221-225.
96. Arai S, Abe K, Kanazawa K, Yoshikawa T, Watanabe S. Encyclopedia of Functional Food. Tokyo, Japan: Asakura; 2007.
97. Masayuki Y, Osamu M. Development of Medicinal Foods. Tokyo, Japan: CMC; 2007.
98. Inoue M. Active Oxygen and Eat Well and to Be Well. Tokyo, Japan: Kyoritu Shuppan; 1996.
99. Zubair H, Khan HY, Sohail A, et al. Redox cycling of endogenous copper by thymoquinone leads to ROSmediated DNA breakage and consequent cell death: putative anticancer mechanism of antioxidants. Cell Death Dis. 2013;4:e660.
100. Rayman MP. Selenium and human health. Lancet. 2012;37:1256-1268.
101. Muecke R, Micke O, Schomburg L, et al. Impact of treatment planning target volumen (PTV) size on radiation induced diarrhoea following selenium supplementation in gynecologic radiation oncology: a subgroup analysis of a multicenter, phase III trial. Radiat Oncol. 2013;8:72.
102. Muecke R, Micke O, Schomburg L, et al. Multicenter, phase III trial comparing selenium supplementation with observation in gynecologic radiation oncology: follow-up analysis of the survival data 6 years after cessation of randomization. Integr Cancer Ther. 2014;13:463-467.
103. Buntzel J, Riesenbeck D, Glatzel M, et al. Limited effects of selenium substitution in the prevention of radiationassociated toxicities: results of a randomized study in head and neck cancer patients. Anticancer Res. 2010;30:1829-1832.
104. Hu YJ, Chen Y, Zhang YQ, et al. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biol Trace Elem Res. 1997;56:331-341.
105. Sieja K, Talerczyk M. Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy. Gynecol Oncol. 2004;93:320-327.
106. Elsendoorn TJ, Weijl NI, Mithoe S, et al. Chemotherapyinduced chromosomal damage in peripheral blood lymphocytes of cancer patients supplemented with antioxidants or placebo. Mutat Res. 2001;4:145-158.
107. Weijl NI, Elsendoorn TJ, Lentjes EG, et al. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. Eur J Cancer. 2004;40:1713-1723.
108. Truong-Tran AQ, Carter J, Ruffin R, Zalewski PD. New insights into the role of zinc in the respiratory epithelium. Immunol Cell Biol. 2001;79:170-177.
109. Sangthawan D, Phungrassami T, Sinkitjarurnchai W. A randomized double-blind, placebo-controlled trial of zinc sulfate supplementation for alleviation of radiation-induced oral mucositis and pharyngitis in head and neck cancer patients. J Med Assoc Thai. 2013;96:69-76.
110. Ripamonti C, Zecca E, Brunelli C, et al. A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation. Cancer. 1998;82:1938-1945.
111. Lyckholm L, Heddinger SP, Parker G, et al. A randomized, placebo controlled trial of oral zinc for chemotherapy- related taste and smell disorders. J Pain Palliat Care Pharmacother. 2012;26:111-114.
112. Ertekin MV, Koc M, Karslioglu I, Sezen O, Taysi S, Bakan N. The effects of oral zinc sulphate during radiotherapy on anti-oxidant enzyme activities in patients with head and neck cancer: a prospective, randomised, placebo-controlled study. Int J Clin Pract. 2004;58:662-668.
113. Ertekin MV, Uslu H, Karslioglu I, Ozbek E, Ozbek A. Effect of oral zinc supplementation on agents of oropharyngeal infection in patients receiving radiotherapy for head and neck cancer. J Int Med Res. 2003;31:253-266.
114. Ertekin MV, Koc M, Karslioglu I, Sezen O. Zinc sulfate in the prevention of radiation-induced oropharyngeal mucositis: a prospective, placebo-controlled, randomized study. Int J Radiat Oncol Biol Phys. 2004;58:167-174.
115. Halyard MY, Jatoi A, Sloan JA, et al. Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4). Int J Radiat Oncol Biol Phys. 2007;67:1318-1322.
116. DeVita VT, Lawrence ST, Rosenberg SA. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011.
117. Wilson MK, Baguley BC, Wall C, Jameson MB, Findlay MP. Review of high-dose intravenous vitamin C as an anticancer agent. Asia Pac J Clin Oncol. 2014;10:22-37.
118. van Staden SR, Groenewald M, Engelbrecht R, Becker PJ, Hazelhurst LT. Carboxyhaemoglobin levels, health and lifestyle perceptions in smokers converting from tobacco cigarettes to electronic cigarettes. S Afr Med J. 2013;103:865-868.
119. Zhang J, Cao J, Ma S, et al. Tumor hypoxia enhances nonsmall cell lung cancer metastasis by selectively promoting macrophage M2 polarization through the activation of ERK signaling. Oncotarget. 2014;5:9664-9677.
120. Ren T, Zhang W, Liu X, et al. Discoidin domain receptor 2 (DDR2) promotes breast cancer cell metastasis and the mechanism implicates epithelial-mesenchymal transition programme under hypoxia. J Pathol. 2014;234:526-537.
121. Mizutani H. Mechanism of DNA damage and apoptosis induced by anticancer drugs through generation of reactive oxygen species. Yakugaku Zasshi. 2007;127:1837-1842.
122. Conklin KA. Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer. 2000;37:1-18.
123. Hrelia S, Bordoni A, Angeloni C, Leoncini E, Biagi P. Nutritional interventions to counteract oxidative stress in cardiac cells. Ital J Biochem. 2004;53:157-163.
124. Taguchi T, Nazneen A, Abid MR, Razzaque MS. Cisplatinassociated nephrotoxicity and pathological events. Contrib Nephrol. 2005;148:107-121.
125. Jung M, Hotter G, Vinas JL, Sola A. Cisplatin upregulates mitochondrial nitric oxide synthase and peroxynitrite formation to promote renal injury. Toxicol Appl Pharmacol. 2009;234:236-246.
126. Hoshino T, Okamoto M, Sakazaki Y, Kato S, Young HA, Aizawa H. Role of proinflammatory cytokines IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice. Am J Respir Cell Mol Biol. 2009;41:661-670.
127. Rockwell S, Sartorelli AC, Tomasz M, Kennedy KA. Cellular pharmacology of quinone bioreductive alkylating agents. Cancer Metastasis Rev. 1993;12:165-176.
128. Chandel NS, Tuveson DA. The promise and perils of antioxidants for cancer patients. N Engl J Med. 2014;371: 177-178.
129. Nakayama A, Alladin KP, Igbokwe O, White JD. Systematic review: generating evidence-based guidelines on the concurrent use of dietary antioxidants and chemotherapy or radiotherapy. Cancer Invest. 2011;29:655-667.
130. Harvie M. Nutritional supplements and cancer: potential benefits and proven harms. Am Soc Clin Oncol Educ Book. 2014:e478-e486.